Print
Email
Print Edition Stories
MHT's Julie Donnelly: Biotechs lag in social media use
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
After a slow start in 2010, venture capital investment in life sciences is kicking into gear, growing by more than half during the second quarter of the year, according to a report by PricewaterhouseCoopers Pharmaceutical and Life Sciences Industry Group, drawing on data in the recent PricewaterhouseCoopers/National Venture Capital Association/MoneyTree Report.
While the Boston area retained its second place ranking in life sciences investments — behind the San Francisco Bay area — second quarter numbers for Boston bucked the national trend, falling 13 percent to $314 million from the first quarter to the second. Nationally, VC investment in life sciences grew 52 percent from Q1 to Q2 to $2.1 billion in 234 deals. First quarter numbers had reflected a 27 percent dollar-value drop from fourth quarter 2009 figures.
For the first half of 2010, the total investment in life sciences was $3.4 billion, a 26 percent increase versus the same period in 2009, with the total number of deals growing 18 percent to 406.
As it has for five years, life sciences remained the most popular industry segment for VC investment in the second quarter of 2010, with the $2.1 billion in life sciences representing almost one third of the $6.5 billion total across industries.
Within the life sciences segment, the investment split remained consistent in Q2 2010, with biotechnology capturing 63 percent of dollars on 139 deals. Medical devices collected 37 percent of the dollars on 95 deals.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
